US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DTE Energy Company

51.37

0.0000

Volume:- -

Turnover:- -

Market Cap:9.89B

PE:8.14

High:51.37

Open:51.37

Low:51.37

Close:51.37

52wk High:54.73

52wk Low:47.05

Shares:192.58M

Float Shares:191.26M

Volume Ratio:- -

T/O Rate:- -

Dividend:3.85

Dividend Rate:7.49%

EPS(TTM):6.31

EPS(LYR):6.31

ROE:10.39%

ROA:2.72%

PB:0.85

PE(LYR):8.14

Loading ...

Overview Company News Filings

Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain

Benzinga_recent_news

IPO Preview: Focusing on Rare Anti-Cancer Sector, How Much Potential Does Yinpai Pharmaceutical's IPO Story Hold?

Pharma's Direct-To-Patient Wave Hits Novartis Next

Benzinga_recent_news

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US

Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DTP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"DTP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DTP\",,,,,undefined,":{"symbol":"DTP","market":"US","secType":"STK","nameCN":"DTE Energy Company","latestPrice":51.37,"timestamp":1729886400000,"preClose":51.37,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":191263476,"shares":192581931,"eps":6.308108,"marketStatus":"Pre-Mkt","change":0,"latestTime":"02-10 08:18:40 EST","open":51.37,"high":51.37,"low":51.37,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.308108,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770733800000},"marketStatusCode":1,"adr":0,"exchange":"NYSE","adjPreClose":51.37,"dividendRate":0.074898,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DTP\",,,,,undefined,":{"symbol":"DTP","floatShares":191263476,"roa":"2.72%","roe":"10.39%","lyrEps":6.308108,"shares":192581931,"dividePrice":3.8475,"high":51.37,"amplitude":0,"preClose":51.37,"low":51.37,"week52Low":47.05,"pbRate":"0.85","week52High":54.7275,"institutionHeld":0.3036,"latestPrice":51.37,"eps":6.308108,"divideRate":0.074898,"volume":0,"delay":0,"ttmEps":6.308108,"open":51.37,"prevYearClose":51.34},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DTP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2022-11-01","symbol":"DTP","reason":null,"defaultRemindTime":1667309400000,"announcedDate":"2022-10-28","type":"delisting","dateTimestamp":1667275200000},{"market":"US","date":"2022-10-14","symbol":"DTP","amount":0.78125,"defaultRemindTime":1665754200000,"name":"DTE Energy Company","recordDate":"2022-11-01","payableDate":"2022-10-17","currency":"USD","type":"dividend","dateTimestamp":1665720000000},{"market":"US","date":"2022-07-14","symbol":"DTP","amount":0.78125,"defaultRemindTime":1657805400000,"name":"DTE Energy Company","recordDate":"2022-08-01","payableDate":"2022-07-15","currency":"USD","type":"dividend","dateTimestamp":1657771200000},{"market":"US","date":"2022-04-13","symbol":"DTP","amount":0.78125,"defaultRemindTime":1649856600000,"name":"DTE Energy Company","recordDate":"2022-05-01","payableDate":"2022-04-14","currency":"USD","type":"dividend","dateTimestamp":1649822400000},{"market":"US","date":"2022-01-13","symbol":"DTP","amount":0.78125,"defaultRemindTime":1642084200000,"name":"DTE Energy Company","recordDate":"2022-02-01","payableDate":"2022-01-14","currency":"USD","type":"dividend","dateTimestamp":1642050000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DTP\",market:\"US\",,,undefined,":[{"executeDate":"2020-01-14","recordDate":"2020-01-15","paymentDate":"2020-02-01","value":0.78125,"currency":"USD"},{"executeDate":"2020-04-14","recordDate":"2020-04-15","paymentDate":"2020-05-01","value":0.78125,"currency":"USD"},{"executeDate":"2020-07-14","recordDate":"2020-07-15","paymentDate":"2020-08-01","value":0.78125,"currency":"USD"},{"executeDate":"2020-10-14","recordDate":"2020-10-15","paymentDate":"2020-11-01","value":0.78125,"currency":"USD"},{"executeDate":"2021-01-14","recordDate":"2021-01-15","paymentDate":"2021-02-01","value":0.78125,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DTP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DTP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2577318638","title":"Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2577318638","media":"Benzinga_recent_news","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577318638?lang=en_us&edition=fundamental","pubTime":"2025-10-23 02:35","pubTimestamp":1761158100,"startTime":"0","endTime":"0","summary":"Novartis' Cosentyx Phase 3 REPLENISH trial for polymyalgia rheumatica met primary and secondary endpoints, showing significant sustained remission.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/22/Novartis.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/22/Novartis.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/10/48363377/novartis-cosentyx-trial-shows-efficacy-in-patients-with-stiff-joints-and-muscle-pain","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/10/48363377/novartis-cosentyx-trial-shows-efficacy-in-patients-with-stiff-joints-and-muscle-pain","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4532","BK4585","IE0009355771.USD","BK4588","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0320765489.SGD","IE00BFTCPJ56.SGD","BK4007","IE00B4R5TH58.HKD","LU0070302665.USD","LU0211331839.USD","IE00BJT1NW94.SGD","IE0002141913.USD","BK4578","NVS","DTP","LU0208291251.USD"],"gpt_icon":0},{"id":"1181698849","title":"IPO Preview: Focusing on Rare Anti-Cancer Sector, How Much Potential Does Yinpai Pharmaceutical's IPO Story Hold?","url":"https://stock-news.laohu8.com/highlight/detail?id=1181698849","media":"Stock News","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181698849?lang=en_us&edition=fundamental","pubTime":"2025-10-06 16:30","pubTimestamp":1759739451,"startTime":"0","endTime":"0","summary":"Recently, the Hong Kong Stock Exchange welcomed another innovative pharmaceutical company – Nanjing Yinpai Pharmaceutical Co., Ltd. (hereinafter referred to as \"Yinpai Pharmaceutical\") submitted its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DTP"],"gpt_icon":0},{"id":"2571351075","title":"Pharma's Direct-To-Patient Wave Hits Novartis Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2571351075","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571351075?lang=en_us&edition=fundamental","pubTime":"2025-09-30 02:01","pubTimestamp":1759168860,"startTime":"0","endTime":"0","summary":"The Pharmaceutical Research and Manufacturers of America (PhRMA) outlined initiatives to bolster U.S. manufacturing, ease patient costs, and improve access to medicine.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/29/Novartis.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/29/Novartis.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/09/47925052/pharmas-direct-to-patient-wave-hits-novartis-next","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/09/47925052/pharmas-direct-to-patient-wave-hits-novartis-next","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["IE0009355771.USD","IE00B2B36J28.USD","NVS","LU0320765489.SGD","DTP","IE00B4R5TH58.HKD","BK4578","IE00BFTCPJ56.SGD","BK4585","LU0208291251.USD","IE0002141913.USD","LU0211331839.USD","IE00BJJMRZ35.SGD","BK4532","LU0070302665.USD","IE00BJT1NW94.SGD","BK4007","BK4588"],"gpt_icon":0},{"id":"2571931333","title":"Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US","url":"https://stock-news.laohu8.com/highlight/detail?id=2571931333","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571931333?lang=en_us&edition=fundamental","pubTime":"2025-09-29 20:15","pubTimestamp":1759148100,"startTime":"0","endTime":"0","summary":"Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025DTP offering to expand to other appropriate products; explori","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/29/3157703/0/en/Novartis-to-Launch-Direct-to-Patient-Platform-for-Cosentyx-secukinumab-in-the-US.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DTP","AS","BK4202"],"gpt_icon":0},{"id":"2561387994","title":"Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2561387994","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561387994?lang=en_us&edition=fundamental","pubTime":"2025-08-21 07:57","pubTimestamp":1755734220,"startTime":"0","endTime":"0","summary":"Product sales from Olverembatinib in the first half of 2025 increased93% year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverageCommenced commerc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/20/3136791/0/en/Ascentage-Pharma-Reports-2025-Interim-Unaudited-Six-Months-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU1599440770.SGD","BK4581","LU2237443465.HKD","SG9999001424.SGD","BK4533","LU1883839398.USD","LU1880398554.USD","IE00B42XCP33.USD","LU1235294995.USD","LU2462157665.USD","BK4612","LU2237443895.HKD","LU2237443978.SGD","IE00BGHQF631.EUR","LU1430594728.SGD","BK4515","IE00BVYPNW00.USD","LU1046421795.USD","DTP","LU0823417737.USD","LU1571399168.USD","LU1894683264.USD","SG9999015978.USD","BK4534","LU1059921491.USD","LU1823568750.SGD","BK4527","LU1066051811.HKD","LU1778281490.HKD","BK4203","LU1894683348.USD","IE00BKVL7J92.USD","LU1032955483.USD","IE00BDGV0183.EUR","BK4020","CSCO","LU0868494708.USD","LU1196500208.SGD","LU0234572021.USD","LU0942090050.USD","LU1267930813.SGD","BK4560","AAPG","IE00BFMHRM44.USD","LU1880398471.USD","LU1674673428.USD","SG9999001440.SGD","LU2237443622.USD","HR"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}